Pinnbrook Capital Management LP Purchases Shares of 225,320 Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Pinnbrook Capital Management LP purchased a new position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 225,320 shares of the company's stock, valued at approximately $4,966,000.

Several other hedge funds also recently bought and sold shares of TEVA. Creative Planning boosted its holdings in shares of Teva Pharmaceutical Industries by 4.5% during the third quarter. Creative Planning now owns 42,815 shares of the company's stock worth $772,000 after purchasing an additional 1,863 shares during the last quarter. Claro Advisors LLC acquired a new stake in shares of Teva Pharmaceutical Industries during the third quarter worth $52,000. Blue Trust Inc. boosted its holdings in shares of Teva Pharmaceutical Industries by 40.1% during the third quarter. Blue Trust Inc. now owns 14,619 shares of the company's stock worth $263,000 after purchasing an additional 4,185 shares during the last quarter. Raymond James & Associates boosted its holdings in Teva Pharmaceutical Industries by 25.1% in the third quarter. Raymond James & Associates now owns 1,020,719 shares of the company's stock valued at $18,393,000 after acquiring an additional 204,775 shares during the last quarter. Finally, Sequoia Financial Advisors LLC boosted its holdings in Teva Pharmaceutical Industries by 0.7% in the third quarter. Sequoia Financial Advisors LLC now owns 112,380 shares of the company's stock valued at $2,025,000 after acquiring an additional 805 shares during the last quarter. Hedge funds and other institutional investors own 54.05% of the company's stock.

Analyst Ratings Changes

TEVA has been the topic of several research reports. Barclays cut their price objective on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating on the stock in a research report on Thursday, January 30th. StockNews.com lowered Teva Pharmaceutical Industries from a "strong-buy" rating to a "buy" rating in a research report on Wednesday, December 18th. UBS Group dropped their target price on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating on the stock in a research report on Thursday, January 30th. Finally, Piper Sandler lifted their target price on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an "overweight" rating in a research report on Friday, January 17th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $23.57.

Insider Transactions at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, Director Roberto Mignone sold 286,000 shares of the company's stock in a transaction on Friday, December 20th. The stock was sold at an average price of $22.01, for a total value of $6,294,860.00. Following the transaction, the director now owns 695,000 shares of the company's stock, valued at approximately $15,296,950. This represents a 29.15 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.55% of the company's stock.

Teva Pharmaceutical Industries Stock Performance

TEVA stock traded down $0.21 during midday trading on Friday, reaching $16.80. The company had a trading volume of 2,518,834 shares, compared to its average volume of 12,834,438. The company has a quick ratio of 0.75, a current ratio of 0.98 and a debt-to-equity ratio of 2.97. The stock has a 50 day moving average price of $19.92 and a 200 day moving average price of $18.48. Teva Pharmaceutical Industries Limited has a fifty-two week low of $12.51 and a fifty-two week high of $22.80. The firm has a market capitalization of $19.03 billion, a PE ratio of -11.58, a P/E/G ratio of 1.39 and a beta of 0.71.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. Analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.61 earnings per share for the current year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.